Related Experiment Video

Updated: Jul 2, 2026

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
12:27

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

Published on: June 8, 2022

Roles of bioactive sphingolipids in cancer biology and therapeutics

Sahar A Saddoughi1, Pengfei Song, Besim Ogretmen

  • 1Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.

Sub-Cellular Biochemistry
|August 30, 2008
PubMed

Insights

Bioactive sphingolipids, like ceramide and sphingosine 1-phosphate (S1P), are key regulators of cancer. Understanding their metabolism offers new therapeutic strategies to combat cancer growth and drug resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Sphingolipids are critical bioactive molecules influencing cell growth, proliferation, and cancer therapeutics.
  • Ceramide and sphingosine 1-phosphate (S1P) are central sphingolipids with opposing roles in cancer.
  • Dysregulation of sphingolipid metabolism is linked to cancer progression and therapeutic resistance.

Purpose of the Study:

  • To review the roles of bioactive sphingolipids in cancer pathogenesis and therapy.
  • To highlight the regulatory network of enzymes involved in sphingolipid metabolism.
  • To explore the potential of targeting sphingolipid metabolism for novel cancer treatments.

Main Methods:

  • Literature review of studies on sphingolipid metabolism and cancer.
  • Analysis of the biochemical pathways regulating ceramide and S1P.
  • Examination of the link between sphingolipid levels and drug resistance.

Main Results:

  • Ceramide generally inhibits cancer cell growth, induces apoptosis, and modulates senescence.
  • Sphingosine 1-phosphate (S1P) promotes cancer cell transformation, growth, and angiogenesis.
  • Reduced ceramide and elevated S1P levels are associated with resistance to apoptosis and therapeutic failure.

Conclusions:

  • Sphingolipid metabolism is a critical determinant of cancer progression and response to therapy.
  • Targeting enzymes in the sphingolipid metabolic network presents a promising therapeutic avenue.
  • Further understanding of sphingolipid function may lead to strategies to overcome drug resistance in cancer.

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their access...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...